Neuropathic Pain News and Research RSS Feed - Neuropathic Pain News and Research

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit. [More]
United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. [More]
Study demonstrates that activation of cannabinoid CB2 receptors suppresses chronic pain

Study demonstrates that activation of cannabinoid CB2 receptors suppresses chronic pain

Medical marijuana is proliferating across the country due to the ability of cannabis ingestion to treat important clinical problems such as chronic pain. However, negative side effects and the development of tolerance limit the widespread therapeutic use of Δ9-tetrahydrocannabinol (Δ9-THC), the major psychoactive ingredient in cannabis. [More]
Two Glenmark manufacturing facilities in India win Greentech Environment Gold Award - 2015

Two Glenmark manufacturing facilities in India win Greentech Environment Gold Award - 2015

Two manufacturing facilities of Glenmark located in Goa and Nashik bagged the prestigious 'Greentech Environment Gold Award - 2015' for Excellence in Environment Management at a ceremony in Kolkata recently. Greentech Environment Awards are presented ever year to companies/units in India demonstrating the highest level of commitment to Environmental Management across different sectors. [More]
International study shows potential new therapy to treat patients with neuropathic pain

International study shows potential new therapy to treat patients with neuropathic pain

An international study led by scientists at McGill University reports, for the first time, that drugs that selectively target the melatonin MT2 receptor represent a novel class of analgesic drugs that could be used to treat patients with neuropathic pain. [More]
New compound may lead to development of potential therapeutics for neuropathic pain

New compound may lead to development of potential therapeutics for neuropathic pain

A new compound discovered by a team of UC Davis investigators has potent actions against production of a chemical that which is implicated in the development of chronic pain following a peripheral nerve injury in the spinal cord. [More]
Unmet medication need in neuropathic pain

Unmet medication need in neuropathic pain

A systematic review and meta-analysis reveals that current treatments for neuropathic pain achieve only a moderate response in patients. [More]
ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290. [More]
Report supports potential of focused ultrasound to treat certain OCD patients

Report supports potential of focused ultrasound to treat certain OCD patients

A recently published report in the Journal of Molecular Psychiatry supports the potential of focused ultrasound to treat certain patients with obsessive-compulsive disorder (OCD). [More]
BUSM's Carmela Abraham receives 2014 Massachusetts Neuroscience Consortium Award

BUSM's Carmela Abraham receives 2014 Massachusetts Neuroscience Consortium Award

Carmela Abraham, PhD, professor of biochemistry and pharmacology at Boston University School of Medicine, was one of six recipients of this year's Massachusetts Neuroscience Consortium Award out of nearly 60 applicants. The grant was awarded to her for her work on multiple sclerosis and the role of the life extension protein Klotho in the limited repair of white matter in the disease. [More]
Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million. [More]
SLU researcher discovers way to block pain pathway

SLU researcher discovers way to block pain pathway

In research published in the medical journal Brain, Saint Louis University researcher Daniela Salvemini, Ph.D. and colleagues within SLU, the National Institutes of Health and other academic institutions have discovered a way to block a pain pathway in animal models of chronic neuropathic pain including pain caused by chemotherapeutic agents and bone cancer pain suggesting a promising new approach to pain relief. [More]
Study opens door to new treatments for brain diseases

Study opens door to new treatments for brain diseases

Delivering life-saving drugs across the blood-brain barrier (BBB) might become a little easier thanks to a new report published in the November 2014 issue of The FASEB Journal. [More]
Lpath closes $12.5 million registered direct offering

Lpath closes $12.5 million registered direct offering

Lpath, Inc., the industry leader in bioactive lipid-targeted therapeutics, announced today the closing of its previously announced $12.5 million registered direct offering. [More]
Neuropathic pain phenotype identified in knee osteoarthritis

Neuropathic pain phenotype identified in knee osteoarthritis

Some patients with knee osteoarthritis may experience neuropathic-like symptoms associated with central pain processing, reflecting a discrete phenotype, study findings suggest. [More]
Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune Pharmaceuticals Inc. announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC). [More]
Adding common epilepsy drug to morphine can result in better pain control, say IU researchers

Adding common epilepsy drug to morphine can result in better pain control, say IU researchers

Adding a common epilepsy drug to a morphine regimen can result in better pain control with fewer side effects. Moreover, the combination can reduce the dosage of the opioid needed to be effective, according to a team of pain researchers at Indiana University. [More]
MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. [More]
Neuroscientist discovers new mechanism that can reverse chronic pain

Neuroscientist discovers new mechanism that can reverse chronic pain

It's in the brain where we perceive the unpleasant sensations of pain, and researchers have long been examining how calcium channels in the brain and peripheral nervous system contribute to the development of chronic pain conditions. [More]
Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. [More]
Advertisement
Advertisement